vTv Therapeutics Inc.
For the period ended Mar 10, 2026. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 10, 2026 · Filed Mar 10, 2026
VTVT$21.03-3.3%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except per share data)
(in thousands, except per share data)
| Three Months EndedDecember 31, | For the Year EndedDecember 31, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| (Unaudited) | ||||
| Revenue | $— | $17 | $— | $1,017 |
| Operating expenses: | ||||
| Research and development | 3,908 | 2,234 | 17,861 | 11,546 |
| General and administrative | 3,977 | 2,675 | 14,947 | 13,651 |
| Total operating expenses | 7,885 | 4,909 | 32,808 | 25,197 |
| Operating loss | (7,885) | (4,892) | (32,808) | (24,180) |
| Interest income | 865 | 429 | 1,870 | 1,565 |
| Interest expense | (1) | — | (6) | — |
| Other (expense) income, net | (117) | 26 | (136) | 10 |
| Loss before income taxes | (7,138) | (4,437) | (31,080) | (22,605) |
| Income tax provision | — | — | — | 100 |
| Net loss before noncontrolling interest | (7,138) | (4,437) | (31,080) | (22,705) |
| Less: Net loss attributable to noncontrolling interest | — | (803) | (4,106) | (4,243) |
| Net loss attributable to vTv Therapeutics Inc. | $(7,138) | $(3,634) | $(26,974) | $(18,462) |
| Net loss attributable to vTv Therapeutics Inc. common shareholders | $(7,138) | $(3,634) | $(26,974) | $(18,462) |
| Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted | $(0.58) | $(0.55) | $(3.20) | $(3.20) |
| Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted | 12,408,696 | 6,582,844 | 8,423,632 | 5,771,052 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.